Reference : The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by I...
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin. Implications for Antiangiogenic Strategies
Bajou, Khalid mailto [Université de Liège - ULiège > Département des sciences de la vie > Biologie et génétique moléculaire >]
Masson, Véronique [Centre Hospitalier Universitaire de Liège - CHU > > Gynécologie-Obstétrique CHR >]
Gerard, R. D. [> > > >]
Schmitt, P. M. [> > > >]
Albert, V. [> >]
Praus, M. [> > > >]
Lund, L. R. [> > > >]
Frandsen, T. L. [> > > >]
Brunner, N. [> > > >]
Dano, K. [> > > >]
Fusenig, N. E. [> > > >]
Weidle, U. [> > > >]
Carmeliet, G. [> > > >]
Loskutoff, D. [> > > >]
Collen, D. [> > > >]
Carmeliet, P. [> > > >]
Foidart, Jean-Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement >]
Noël, Agnès mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >]
Journal of Cell Biology
Rockefeller University Press
Yes (verified by ORBi)
New York
[en] angiogenesis ; tumor invasion ; proteolysis ; migration ; serine protease
[en] The plasminogen (Plg)/plasminogen activator (PA) system plays a key role in cancer progression, presumably via mediating extracellular matrix degradation and tumor cell migration. Consequently, urokinase-type PA (uPA)/plasmin antagonists are currently being developed for suppression of tumor growth and angiogenesis. Paradoxically, however, high levels of PA inhibitor 1 (PAI-1) are predictive of a poor prognosis for survival of patients with cancer. We demonstrated previously that PAI-1 promoted tumor angiogenesis, but by an unresolved mechanism. We anticipated that PAI-1 facilitated endothelial cell migration via its known interaction with vitronectin (VN) and integrins. However, using adenoviral gene transfer of PAI-1 mutants, we observed that PAI-1 promoted tumor angiogenesis, not by interacting with VN, but rather by inhibiting proteolytic activity, suggesting that excessive plasmin proteolysis prevents assembly of tumor vessels. Single deficiency of uPA, tissue-type PA (tPA), uPA receptor, or VN, as well as combined deficiencies of uPA and tPA did not impair tumor angiogenesis, whereas lack of Plg reduced it. Overall, these data indicate that plasmin proteolysis, even though essential, must be tightly controlled during tumor angiogenesis, probably to allow vessel stabilization and maturation. These data provide insights into the clinical paradox whereby PAI-1 promotes tumor progression and warrant against the uncontrolled use of uPA/plasmin antagonists as tumor angiogenesis inhibitors.

File(s) associated to this reference

Fulltext file(s):

Open access
BAJOU K et al, J Cell Biol, 152, 777, 2001.pdfPublisher postprint757.04 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.